Tarsus Pharmaceuticals, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:TARS
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 513 out of 853
Universe
Global Universe 11425 out of 15120
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
AstraZeneca Pharma India Ltd. |
29.3
Medium
|
403 out of 853 |
Lotus Pharmaceutical Co., Ltd. |
32
High
|
512 out of 853 |
Tarsus Pharmaceuticals, Inc. |
32
High
|
513 out of 853 |
Zhejiang Medicine Co., Ltd. |
32.5
High
|
535 out of 853 |
China Resources Boya Bio-pharmaceutical Group Co., Ltd. |
35.5
High
|
675 out of 853 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Tarsus Pharmaceuticals, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Tarsus Pharmaceuticals, Inc.'s Management of ESG Material Risk is Average